Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.86 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.86 |
| ▸ | MEN1 | O00255 | 2/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.79 |
| ▸ | OPRD1 | P41143 | 11/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.66 |
| ▸ | HTR1A | P08908 | 2/20 | 0.66 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.66 |
| ▸ | DRD1 | P21728 | 2/20 | 0.66 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.66 |
| ▸ | DRD3 | P35462 | 2/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.66 |
| ▸ | BCL2 | P10415 | 1/20 | 0.66 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norchlorcyclizine SCHEMBL467086 | 1.00 | CYP2D6 (0.86) | CYP2D6CYP19A1MEN1KMT2AOPRD1 | |
| Norchlorcyclizine SCHEMBL6556514 | 1.00 | CYP2D6 (0.86) | CYP2D6CYP19A1MEN1KMT2AOPRD1 | |
| Norchlorcyclizine SCHEMBL4649874 | 0.98 | CYP2D6 (0.83) | CYP2D6CYP19A1MEN1KMT2AOPRD1 | |
| Norchlorcyclizine SCHEMBL588155 | 0.98 | CYP2D6 (0.83) | CYP2D6CYP19A1MEN1KMT2AOPRD1 | |
| Norchlorcyclizine SCHEMBL7139140 | 0.97 | CYP2D6 (0.81) | CYP2D6CYP19A1MEN1KMT2AOPRD1 | |
| SCHEMBL5363117 | 0.94 | CYP2D6 (0.76) | CYP2D6CYP19A1MEN1KMT2AOPRD1 | |
| SCHEMBL1137956 | 0.93 | CYP2D6 (1.00) | CYP2D6CYP19A1MEN1KMT2AOPRD1 | |
| Norchlorcyclizine SCHEMBL7989702 | 0.92 | CYP2D6 (0.73) | CYP2D6CYP19A1MEN1KMT2AOPRD1 | |
| Norchlorcyclizine SCHEMBL7993069 | 0.91 | CYP2D6 (0.71) | CYP2D6CYP19A1MEN1KMT2AOPRD1 | |
| Norchlorcyclizine SCHEMBL2426579 | 0.90 | CYP2D6 (0.69) | CYP2D6CYP19A1MEN1KMT2AOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117209453-A | Preparation and application of levocetirizine hydrochloride intermediate | 迪嘉药业集团股份有限公司 | 2023-12-12 | — | — | CN | claimed |
| CN-115417824-A | High-purity preparation method of rosuvastatin intermediate | 安徽美诺华药物化学有限公司 | 2022-12-02 | — | — | CN | claimed |
| WO-2009078627-A2 | METHOD FOR PREPARING (R)-(-)-1-[(4-CHLOROPHENYL)PHENYLMETHYL]PIPERAZINE | HANMI PHARM. CO., LTD. (KR) | 2009-06-25 | — | — | WO | claimed |
| US-11866430-B2 | Naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-09 | — | — | US | disclosed |
| CN-117209453-A | Preparation and application of levocetirizine hydrochloride intermediate | 迪嘉药业集团股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-112585139-B | Naphthyridinone compounds as T cell activators | 百时美施贵宝公司 | 2023-12-01 | — | — | CN | disclosed |
| EP-3814347-B1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-05-03 | — | — | EP | disclosed |
| WO-2023068839-A1 | FILM-COATED TABLET WITH IMPROVED STABILITY CONTAINING MONTELUKAST OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND LEVOCETIRIZINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 한화제약주식회사 | 2023-04-27 | — | — | WO | disclosed |
| CN-115417824-A | High-purity preparation method of rosuvastatin intermediate | 安徽美诺华药物化学有限公司 | 2022-12-02 | — | — | CN | disclosed |
| CN-115417824-A | High-purity preparation method of rosuvastatin intermediate | 安徽美诺华药物化学有限公司 | 2022-12-02 | — | — | CN | disclosed |
| US-20170001988-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2017-01-05 | — | — | US | disclosed |
| EP-1165533-B1 | COMPOUNDS AND METHODS FOR TREATMENT OF ASTHMA, ALLERGY AND INFLAMMATORY DISORDERS | UCB SA (BE) | 2004-10-13 | — | — | EP | disclosed |
| US-6797713-B2 | Compounds and methods for treatment of asthma, allergy and inflammatory disorders | UCB S.A. (BE) | 2004-09-28 | — | — | US | disclosed |
| EP-1418173-A1 | N-(3-butyn-1-yl) N-hydroxyurea | UCB, S.A. (BE) | 2004-05-12 | — | — | EP | disclosed |
| US-20040048875-A1 | Compounds and methods for treatment of asthma, allergy and inflammatory disorders | UCB S.A. | 2004-03-11 | — | — | US | disclosed |
| US-6686502-B1 | N-HYDROXYL-N-(3-BUTYNYL)-UREA CHEMICAL INTERMEDIATE FOR PIPERIDINE OR PIPERAZINE DERIVATIVES | UCB S.A. (BE) | 2004-02-03 | — | — | US | disclosed |
| US-20030220347-A1 | Compounds and methods for treatment of asthma, allergy and inflammatory disorders | UCB S.A. | 2003-11-27 | — | — | US | disclosed |
| US-6451801-B1 | 1,4-SUBSTITUTED PIPERIDINES AND PIPERAZINES | UCB, S.A. (BE) | 2002-09-17 | — | — | US | disclosed |
| EP-1165533-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF ASTHMA, ALLERGY AND INFLAMMATORY DISORDERS | UCB, S.A. (BE) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000058295-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF ASTHMA, ALLERGY AND INFLAMMATORY DISORDERS | UCB, S.A. (BE) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001988-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | NCOR1, RRP15, NCOA1 | CYP2D6 1663/4885CYP19A1 1222/4885MEN1 3157/4885 |
| US-20030220347-A1 | Compounds and methods for treatment of asthma, allergy and inflammatory disorders | HRH4, HRH2, HRH3 | CYP2D6 1728/4885CYP19A1 1396/4885MEN1 2857/4885 |
| US-11866430-B2 | Naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | CYP2D6 4190/4885CYP19A1 2663/4885MEN1 2238/4885 |
| US-20040048875-A1 | Compounds and methods for treatment of asthma, allergy and inflammatory disorders | HRH4, HRH2, HRH3 | CYP2D6 1728/4885CYP19A1 1396/4885MEN1 2857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.